Sign Out
Prevent or modify measles attack in immunocompromised patients
Adult: For prevention of an attack: 750 mg as an IM inj; to be given within 6 days after exposure (better efficacy if given within 72 hr). To modify an attack: 250 mg as an IM inj.
Child: For prevention of an attack: <1 yr: 250 mg; 1-2 yr: 500 mg; ≥3 yr: 750 mg, as a single IM inj. Dose should be given within 6 days after exposure (better efficacy if given within 72 hr). To modify an attack: <1 yr: 100 mg and ≥1 yr: 250 mg, as a single IM inj.
Child: For prevention of an attack: <1 yr: 250 mg; 1-2 yr: 500 mg; ≥3 yr: 750 mg, as a single IM inj. Dose should be given within 6 days after exposure (better efficacy if given within 72 hr). To modify an attack: <1 yr: 100 mg and ≥1 yr: 250 mg, as a single IM inj.
Intramuscular
Control outbreaks of hepatitis A, Prophylaxis against hepatitis A in immunocompromised patients
Adult: Recommended dose: 500 mg via deep IM inj.
Child: Recommended dose: <10 yr: 250 mg; ≥10 yr: 500 mg, to be given as deep IM inj.
Child: Recommended dose: <10 yr: 250 mg; ≥10 yr: 500 mg, to be given as deep IM inj.
Intramuscular
Primary rubella in pregnant women whereby pregnancy termination is unacceptable
Adult: 750 mg as an IM inj.
Intravenous
Raise platelet count in patients with idiopathic thrombocytopenic purpura
Adult: 400 mg/kg/day for 2-5 consecutive days. Alternatively, a dose of 800-1000 mg/kg may be given on day 1 and repeated on day 3 if needed. Doses to be given via IV infusion. Treatment may be repeated if relapse occurs.
Intravenous
Guillain-Barre syndrome
Adult: 400 mg/kg daily for 5 consecutive days, may repeat every 4 wk if needed.
Intravenous
Kawasaki disease
Adult: 1.6-2 g/kg in divided doses over 2-5 days, or 2 g/kg given as a single dose. To be used in conjunction with acetylsalicylic acid.
Intravenous
Allogenic bone marrow transplantation
Adult: As part of the conditioning regimen and after transplantation: 500 mg/kg/wk, starting 7 days before transplantation and for up to 3 mth after transplantation. In cases of persistent lack of antibody production, 500 mg/kg/mth may be used to normalise the antibody level.
Intravenous
Prophylaxis of infections after bone marrow transplantation
Adult: 500 mg/kg/wk, adjust dose according to response.
Parenteral
Immunocompromised patients or patients with primary antibodies deficiency
Adult: IV admin: Initially, 400-800 mg/kg, then 200 mg/kg every 3 wk, adjust according to trough-immunoglobulin levels; maintenance dose: 200-800 mg/kg/mth. In patients with secondary immunodeficiency syndromes: 200-400 mg/kg every 3-4 wk may be used. Alternatively, dose may be given via SC admin: Initial loading dose of 200-500 mg/kg (divided over several days), followed by maintenance doses at repeated intervals to achieve a cumulative mthly dose of 400-800 mg/kg.
